

# Anti-PDCD1 / PD-1 / CD279 Reference Antibody (pembrolizumab)

Recombinant Antibody  
Catalog # APR10246

## Product Information

---

<b>Application</b>	FC, Kinetics, Animal Model
<b>Primary Accession</b>	<a href="#">Q15116</a>
<b>Reactivity</b>	Human
<b>Clonality</b>	Monoclonal
<b>Isotype</b>	IgG4SP
<b>Calculated MW</b>	31647

## Additional Information

---


<b>Target/Specificity</b>	PDCD1 / PD-1 / CD279
<b>Endotoxin Conjugation</b>	Unconjugated
<b>Expression system</b>	CHO Cell
<b>Format</b>	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

## Protein Information


---

<b>Name</b>	PDCD1 {ECO:0000303   PubMed:7851902, ECO:0000312   HGNC:HGNC:8760}
<b>Function</b>	Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self (PubMed: <a href="#">21276005</a> , PubMed: <a href="#">31754127</a> , PubMed: <a href="#">32184441</a> , PubMed: <a href="#">37208329</a> ). Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed: <a href="#">21276005</a> , PubMed: <a href="#">26602187</a> ). Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation (PubMed: <a href="#">32184441</a> ). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (PubMed: <a href="#">32184441</a> ).
<b>Cellular Location</b>	Cell membrane; Single-pass type I membrane protein


# Images




Anti-PDCD1 / PD-1 / CD279 Reference Antibody (pembrolizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-PDCD1 / PD-1 / CD279 Reference Antibody (pembrolizumab) is more than 95%, determined by SEC-HPLC.



Immobilized human PD-1 His at 2 µg/mL can bind Anti-PDCD1 / PD-1 / CD279 Reference Antibody (pembrolizumab),  $EC_{50}=0.0039$  µg/mL



Pembrolizumab inhibited the tumor growth of MC38 on human PD-1 mice. The result showed significant anti-tumor effects, with a tumor inhibition rate (TGI) of 44.0% at 0.18 mpk at D37.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.